Drug Profile
Research programme: carbohydrate-targeted nanocarrier - Rodos BioTarget
Alternative Names: RBT-05; TargoSphere-encapsulated RBT05; TargoVirLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Rodos BioTarget
- Class
- Mechanism of Action C-type lectin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C; HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in Germany
- 03 Dec 2010 Research programme: carbohydrate-targeted nanocarrier - Rodos BioTarget is available for licensing as of 03 Dec 2010. http://www.biotargeting.eu